Clinical trials: Anastrozole
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
This study is open to women who have early-stage breast cancer and are on aromatase inhibitor (AI) therapy, and who have hypoactive sexual desire disorder (HSDD).
- Conditions
- Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
- Trial name
- NCT07596212
- Testing
- Aromatase Inhibitors, Bupropion, GnRH agonist
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS).
- Conditions
- Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01824836
- Testing
- anastrozole
- Where
- 2 sites in United States
- Volunteers
- 1,046 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
To evaluate the antitumor activity, toxicity, and effectiveness of the combination of goserelin (Zoladex) and anastrozole (Arimidex) in the treatment of premenopausal women with hormone receptor positive metastatic carcinoma of…
- Trial name
- NCT00186121
- Testing
- Anastrozole (Arimidex), Goserelin (Zoladex)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Breast Cancer
Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients
1. Women with operable breast cancer with a 2-8 week preoperative waiting period will accept preoperative therapy trials and specifically taking a standard drug for breast cancer such as anastrozole in this study 2.
- Trial name
- NEO ER 11-05 (NCT01972984)
- Testing
- Anastrozole
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin and anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217659
- Testing
- anastrozole, goserelin acetate
- Where
- 57 sites in United States
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after treatment of an aromatase inhibitor.
- Trial name
- BETTER (NCT02910050)
- Testing
- Bicalutamide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Xu fei
Breast Cancer
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer…
- Trial name
- NCT01207635
- Testing
- Ductal Lavage Fluid Collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
To compare the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer
- Trial name
- RIGHT Choice (NCT03839823)
- Testing
- Docetaxel / Capecitabine, Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine
- Where
- 50 sites in Egypt, India and 11 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
The study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma
- Trial name
- NCT01953588
- Testing
- fulvestrant, anastrozole
- Where
- 860 sites in United States, Puerto Rico
- Volunteers
- 1,473 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00244959
- Testing
- anastrozole, adjuvant therapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
The purpose of this pilot study is to see if taking anastrozole (Arimidex) for 10 days causes changes in breast cancer cells. Anastrozole (Arimidex) is a drug used in the treatment of a type of breast cancer that depends on…
- Trial name
- NCT00588003
- Testing
- anastrozole
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Breast Cancer, Stage IA Breast Cancer
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole.
- Conditions
- Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01478477
- Testing
- omega-3 fatty acid supplement, Clinical assessments, Assessment of therapy complications
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Breast Cancer
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
CDK4/6 inhibitors are currently the standard treatment for female breast cancer patients with HR+ tumors. However, there is no established standard treatment for patients who experience treatment failure with CDK4/6 inhibitors.
- Trial name
- NCT05861830
- Testing
- The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy selected by the physician
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Healthy
Anastrozole 1 mg Tablets Under Fasting Conditions
The objective of this study is to evaluate the comparative bioavailability between Anastrozole 1 mg Tablets (Teva Pharmaceuticals USA) and Arimidex® 1 mg Tablets (AstraZeneca Pharmaceuticals LP, USA), after a single-dose in…
- Trial name
- NCT01182181
- Testing
- Anastrozole (Teva Pharmaceuticals USA), Anastrozole (Arimidex®)
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Early Breast Cancer
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free…
- Trial name
- Adjuvant WIDER (NCT05827081)
- Testing
- Ribociclib, Letrozole, Ansastrozole
- Where
- 214 sites in United States, Argentina and 14 more
- Volunteers
- 1,464 people
- Sponsor
- Novartis Pharmaceuticals
Safety, Pharmacokinetics
Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects
This study is to investigate whether anastrozole ODF is bioequivalent with Arimidex tablet after a single oral administration of each anastrozole formulation.
- Trial name
- NCT01568281
- Testing
- Anastrozole ODF, Arimidex tablet
- Where
- Japan
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Advanced Breast Cancer
CB-103 Plus NSAI In Luminal Advanced Breast Cancer
Multicenter, single-arm, open label, phase II clinical trial with safety run-in to evaluate the safety, tolerability, pharmacokinetics and efficacy of CB-103 in combination with a non-steroidal aromatase inhibitor (NSAI)…
- Trial name
- CAILA (NCT04714619)
- Testing
- CB-103
- Where
- 2 sites in Spain
- Volunteers
- 2 people
- Sponsor
- MedSIR
Breast Cancer
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safety of giredestrant (A) versus giredestrant plus triptorelin (B) versus…
- Trial name
- PREcoopERA (NCT05896566)
- Testing
- Giredestrant, Triptorelin, Anastrozole
- Where
- 37 sites in France, Germany and 4 more
- Volunteers
- 231 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal…
- Trial name
- NCT00295646
- Testing
- tamoxifen, anastrozole, zoledronic acid
- Where
- 72 sites in Austria, Germany
- Volunteers
- 1,803 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer (Early Breast Cancer)
Skipping Hormone Therapy in Low-Risk Early Breast Cancer
The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse.
- Trial name
- NoELA (NCT07661927)
- Testing
- Removing Endocrine Therapy
- Where
- 41 sites in France
- Volunteers
- 700 people
- Sponsor
- UNICANCER